Ursodiol in Huntington's Disease

Status unconfirmed · Phase 1 · Has a placebo group

Conditions studied: Huntington Disease

In brief

The purpose of this study is to evaluate the safety of the drug ursodiol (ursodeoxycholic acid, UDCA) in people with Huntington's disease (HD) and to explore how the compound is processed by the body.

Key facts

Study ID

NCT00514774

Run by

Oregon Health and Science University

People needed

21

Starts

2007-08-01

Expected to finish

2009-06-01

Last updated by the study team

2009-02-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All subjects will be age 18 or older
• All subjects will have manifest Huntington disease determined by clinical exam plus either documented prior DNA testing for the HD gene or a documented family history of the disease

You may not qualify if…

• Subjects taking oral contraceptives, cholestyramine, colestipol, or aluminum-based antacids will be excluded
• Subjects with known allergy or other contraindication to the study drug will be excluded
• Subjects with bleeding diathesis, or on coumadin or mandatory aspirin will be excluded
• Subjects with unstable medical or psychiatric illness will be excluded
• Subjects with clinically significant lab / EKG abnormalities at screening will be excluded
• Subjects who are currently pregnant or breastfeeding will be excluded

Where it is running

• Oregon Health & Science University — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.